Stem Cell Clinic

Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED – Magazine of…

By Stem Cell Medical Center

More than 30 million men are suffering from impotence or erectile dysfunction in the United States.Many men find it difficult to discuss a sexual health problem such as ED. However, its important to discuss your ED openly and honestly with your doctor.Complications resulting from erectile dysfunction can include: an unsatisfactory sex life, stress or anxiety, embarrassment or low self-esteem, relationship problems, the inability to get your partner pregnant.TreatmentsMany men prefer taking pills instead of surgery. Pills are the short-term solution.Valencia Medical Center offers new medical breakthrough procedure that leads to more long-term treatment for erectile dysfunction. Using acoustic wave therapy to repair blood vessels to the genitals.Treatment principals:Initial office visit evaluates your condition and order a comprehensive blood testing including hormone test. The result indicates if any hormonal imbalance such as testosterone exist.The first part of the treatment plan is to restore the hormone deficiency which is essential to recovery of sexual function. Hormone Pellet Therapy is the most effective restoration to last up to six months. Just one treatment every six months to keep balanced. The next step to treat your ED is three to several sessions of 20 to 30 minutes of new acoustic wave therapy, each a few days apart. It is mostly without discomfort, and non-surgical. Many patients show satisfactory improvement in their sexual functions. Patients upon each treatment can continue their normal activities.Stem Cell Therapy using your blood to use growth factor in your stem cells and injected. This procedure has been effective and restores normal functions. Valencia Medical Center offers Care Credit and in-house financing. For more information, please contact Valencia Medical Center at 661-222-9117. The office is located at 24159 Magic Mountain Parkway in Valencia.

Excerpt from:
Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED - Magazine of...

BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT – BioSpace

By Stem Cell Medical Center

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020.

BrainStorms CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer and Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. EDT, Tuesday, May 5, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 1Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

ABOUT NUROWNNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

ABOUT BRAINSTORM CELL THERAPEUTICS INC.:BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

SAFE HARBOR STATEMENT:Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTSInvestor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

More:
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace

Macomb County doctor charged health care fraud over COVID-19 treatments – Detroit Free Press

By Stem Cell Treatment

The founder of Allure Medical Spa, the Shelby Township business raided by federal officials last week, is accused of health care fraud that includes using the COVID-19 pandemic "as an opportunity to bill insurers for Vitamin-C infusions fraudulently represented as COVID-19 treatments and preventative measures."

Dr. Charles Mok is the only defendant listed in the 47-page complaint unsealed Tuesday in U.S. District Court in Detroit. The 56-year-old Washington Township man is charged with health care fraud and conspiracy to commit health care fraud in the complaint dated Friday.

His attorney, Mark Kriger, had no comment Tuesday morning.Mok is scheduled for an initial appearance in court at 1 p.m. Tuesday.

The complaint discusses multiple millions of dollars in billings to Medicare from Jan. 1, 2018 to April 7 of this year.

It alleges that Mok engaged in a scheme to defraud prior to and during the coronavirus pandemic through the submission of false and fraudulent claims to Medicare for payment related to the treatment of varicose veins.

The complaint also states he failed to observe appropriate protocols at the clinic to minimize the spread of the virus.

A cooperating witness, who is an employee, was aware of five employees who tested positive for the virus but continued to work and treat patients at Allure, according to the complaint.

Federal Bureau of Investigations evidence response team members head into the building where Allure Medical's office is in Shelby Township, Michigan on Thursday, April 23, 2020.The Federal Bureau of Investigations raided Allure Medical for an alleged "federal violation."(Photo: Eric Seals, Detroit Free Press)

FBI investigators raided the location near 26 Mile and Van Dyke last Thursday. TheU.S. Department of Health and Human Services was part of the task force.

More: FBI raids Allure Medical Spa in Shelby Township for alleged fraudulent COVID-19 treatments

A woman who answered the phone at the Allure Medical location the day of the raid she did not have anyone available to talk with a Free Press reporter. Messages left at the location and via email that day were not returned.

Allure Medical has eight locations in Michigan, as well as offices in Florida, Kentucky, North Carolina and South Carolina, according to its website.

It statedthe Shelby Township location offers varicose vein treatment, hormone replacement therapy, dermatology, stem cell therapy, cosmetics and weight loss services.

The building where Allure Medical's office is in Shelby Township, Michigan on Thursday, April 23, 2020.The Federal Bureau of Investigations raided Allure Medical for an alleged "federal violation."(Photo: Eric Seals, Detroit Free Press)

According to SRQ Magazine, Allure Medical was offering high-dose intravenous vitamin C therapy to front-line employees who are at risk of contracting the virus and to existing COVID-19 patients. Front-line workers are identified as those who include hospital staff, police and first responders, and grocery store employees.

The magazine quoted Mok as saying We are using high-dose IV vitamin C to help support people's immune systems and to help those with the virus recover quicker. We want to provide this treatment to those who need it, regardless of their ability to pay."

The magazine statedthat Allure Medical won't treat sick people at the same time as those who are healthy.

Contact Christina Hall: chall@freepress.com. Follow her on Twitter: @challreporter.

Read or Share this story: https://www.freep.com/story/news/local/michigan/macomb/2020/04/28/allure-medical-spa-shelby-covid-vitamin-c/3038801001/

Read more:
Macomb County doctor charged health care fraud over COVID-19 treatments - Detroit Free Press

The impact of the coronavirus on the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Volume Analysis, size, share and Key Trends…

By Stem Cell Treatment

Analysis of the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The recent market study suggests that the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is expected to grow at a CAGR of ~XX% between 2019 and 2029 and reach a value of ~US$XX by the end of 2029.

The study offers a microscopic view of the various segments and sub-segments of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market and accurately represents the data using informative tables, graphs, and figures. The objective of the report is to assist readers to make informed business decisions and improve their position in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market landscape post the COVID-19 pandemic.

Request Sample Report @https://www.mrrse.com/sample/18928?source=atm

Vital data enclosed in the report:

Segmentation Analysis of the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market study offers a detailed understanding of the consumption, demand, and pricing structure of each product.

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market report evaluates how the Platelet Rich Plasma and Stem Cell Alopecia Treatment is being utilized by various end-users.

By Region

The report offers valuable insights related to the growth prospects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in different regions including:

Companies Mentioned in the Report

The report also profiles major players operating in the global platelet rich plasma & stem cell alopecia treatment market based on various attributes, such as company overview, financial overview, pipeline portfolio, product portfolio, business strategies, and recent developments. The players covered in the report include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented as below:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/18928?source=atm

Questions Related to the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Catered to in the Report:

Buy This Report @ https://www.mrrse.com/checkout/18928?source=atm

Read the original post:
The impact of the coronavirus on the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Volume Analysis, size, share and Key Trends...

Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) – Jewish Life News

By Stem Cell Treatment

GlobalStem Cell Therapy Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.

MarketInsightsReports has announced the addition of the Global Stem Cell Therapy Market Research Report 2020 The report focuses on global major leading players with information such as company profiles, product picture and specification.

Get Sample Copy of Stem Cell Therapy Market Report

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/inquiry?Mode=10

Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), request free sample for complete list of companies.

The leading players of industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among players will help the industry aspirants in planning their strategies.

Summary

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell Therapy market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell Therapy industry.

Stem Cell Therapy Market Segmentation by types, Applications and regions:

Market Segment by Type covers:

Autologous

Allogeneic

Market Segmented by Applications:

Musculoskeletal Disorder

Wounds & Injuries

Cornea

Cardiovascular Diseases

Others

Market Segment by Regions:

North America (the United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)

Available [emailprotected] (Exclusive new year offer Flat 20%- Use code MIR 20):

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/discount?Mode=10

These segments are thoroughly evaluated on an individual basis and a team of analysts has ensured to give a crystal clear idea about various lucrative segments of the industry. This detailed analysis using segmentation by providing precise results on industry-related markets.

The report also analyzed the evolution of industry trends. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the industry.

Frequently Asked Questions about global market:

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or 3 countries or nearly 40 analyst hours.

Note:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Visit complete report@

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026?Mode=10

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and Chinese and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More:
Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) - Jewish Life News

Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life – Cancer Therapy Advisor

By Stem Cell Treatment

Home Cancer Topics Gynecologic Cancer

Whole-genome DNA sequencing studies of normal endometrial glandulartissue have revealed the frequent presence of somatic driver mutations in cancer-relatedgenes. These findings were published in Nature.

While the acquisition of mutations overtime is believed to be a characteristic of all somatic cells, data are limitedon how it occurs in normal tissues.Nevertheless, the study authors noted that [t]he characterizationof the mutational landscapes of normal tissues isadvancing our understanding of the succession of intermediate neoplastic stages between normalcells and the cancers that originate fromthem.

One of the rationales for focusing on theendometrium of the uterus was related to its highly dynamic physiology duringthe reproductive years in response to fluctuating hormone levels, as well asits composition of stromal cells covered by a surface epithelium that iscontiguous with embedded glandular epithelium. Although the contiguity of thesurface epithelial sheet and the glandular tissue is disrupted duringmenstruation, it is subsequently restored by stem cells within retained embeddedglands.

In this study, 292 normal endometrialglands were isolated using laser-capture microdissection from 28 women between theages of 19 and 81 years. Comparisons of whole-exome DNA sequencing results forthese tissues with matched specimens of other types of normal tissue from thesame individual were used to identify somatic mutations in the endometrialglandular tissue. Corresponding data on patient age and parity allowed for theexploration of these factors on the rate and timing of somatic driver mutationsin normal glandular tissue of the endometrium.

Some of the keyfindings of this study included the following:

In their concluding remarks, the study authors noted that their results show that mutational landscapes differ markedly between normal tissues perhaps shaped by differences in their structure and physiology and indicate that the procession of neoplastic change that leads to endometrial cancer is initiated early in life.

Reference

Moore L, Leongamornlert D, Coorens THH, et al. The mutational landscape of normal human endometrial epithelium [published online April 22, 2020]. Nature. doi: 10.1038/s41586-020-2214-z

Please login or register first to view this content.

LoginRegister

Next post in Gynecologic CancerClose

Continue reading here:
Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life - Cancer Therapy Advisor

Stem Cell Treatment Options | National Stem Cell Clinic

By Stem Cell Medicine

Find The Right Treatment Option Available For You

Dealing with chronic pain might have become routine, but it doesnt have to be your normal anymore. At National Stem Cell Clinic, our doctors have years of experience with regenerative medicine, improving the lives of patients just like you. We treat various areas of the body, including the following:

Degenerative discs often cause chronic neck pain. While surgery is a common solution, we have a less invasive solution with regenerative stem cells. After harvesting stem cells and combining them with growth factors, they are injected directly into the damaged portion of the neck. After about three weeks youll begin to notice results.

Learn more about stem cell therapy for neck pain

Stem cell therapy benefits patients with common shoulder injuries such as dislocations, arthritis, thoracic outlet syndrome, and rotator cuff issues. Unlike full joint replacement or other corrective shoulder surgeries, patients are able to get back to regular activity immediately.

Find out more about stem cell therapy for shoulder pain

Patients who have experienced chronic back pain may have been directed to physical therapy, pain meds, exercise, and other types of therapy. While these treatments assist in improving back function, full restoration rarely takes place. Now, regenerative medicine repairs damaged discs with the recreation of living tissues which are then injected into the damaged portion of the lower back, offering a significantly higher rate of full restoration.

About Our Stem Cell Therapy for Lower Back Pain

Back pain can be a debilitating condition of which people suffer for years on end. Many patients run through a gauntlet of tests and procedures and still find relief to be elusive. Fortunately, with new therapies and technologies, there is hope for sufferers of this chronic condition.

About Our Stem Cell Therapy for Back Pain

While osteoarthritis is a common reason for knee pain, it is often the result of another type of injury. This could include a fracture, a tear in the ligament, a muscle strain, or damage to the tendon. Minimally invasive stem cell injections can help patients suffering from this chronic pain to go from pain to self-recovery in just a few short months.

Learn about our stem cell treatment for knees

Like the knees, a lot of pain in patients is related to osteoarthritis. Individuals report immobility accompanied by painful swelling. Their hips may feel sharp, stabbing pains or dull aches. Other patients have pain caused by a traumatic injury. In either case, stem cell regeneration is a solution in which pain is minimized, tissues are rebuilt, and cartilage cells are replaced. After the procedure, the patients body works to reduce pain and inflammation with the regenerated cells.

Find out more about our stem cell treatments for hips

The elbow is a joint you regularly use, whether youre eating, playing a sport, playing an instrument, or simply using the remote control. If you want to avoid surgery or other invasive treatment options for your elbow pain, regenerative medicine is an option youll appreciate. Patients with golfers elbow, tennis elbow, arthritis, nerve entrapment, and similar elbow issues can get back to normal life immediately following the procedure.

More about our stem cell therapy for elbows

When you want a non-invasive treatment option for issues with your wrist, regenerative stem cells are the way to turn. Patients with trigger finger, instability, TFCC tears, arthritis, and other common wrist conditions can begin to function regularly after their own stem cells are used to repair damaged tissues within the wrist.

Read more about our treatment for wrist pain

When the median nerve in the hand is compressed, patients are often diagnosed with carpal tunnel syndrome. Basic pain, tingling, and numbness are frequently the resulting symptoms, though more severe nerve damage can occur. In any case, patients who are suffering from carpal tunnel can relieve symptoms with stem cell therapies, in which their damage is repaired with living, functional tissues.

Discover our treatment program for carpal tunnel

Your ankles and feet carry a heavy load, so when you begin to feel pain, its important to get treatment right away. Regenerative medicine can be used for ligament sprains, ankle instability, plantar fasciitis, tarsal tunnel syndrome, arthritis, and a variety of other conditions related to the ankle or foot.

More about our ankle and foot pain treatment with stem cells

Regenerative medicine has been found useful for those experiencing hair loss. Doctors reproduce and reintroduce the cells needed to the scalp. The patients previous hair begins to grow, making baldness a thing of the past.

Learn more about treatment for baldness

At National Stem Cell Clinic, we are happy to show you how regenerative medicine can improve your life. Contact us today!

Continue reading here:
Stem Cell Treatment Options | National Stem Cell Clinic

Dr Annalisa Jenkins on healthcare and biotech investments for family offices – Campden FB

By Stem Cell Medicine

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

The pharmaceutical sector has long been attractive for family office investors, either directly or as part of their diversified portfolio. More than a quarter (27%) of families surveyed by Campden Wealth with UBS for The Global Family Office Report 2019 said they directly invested in health care and social assistance. It was the fourth most popular sector for families behind technology (49%), real estate and rental/leasing (42%) and finance and insurance (30%).

Dr Annalisa Jenkins MBBS, MRCP is a life sciences thought leader with more than 25 years of biopharmaceutical industry experience. The former surgeon lieutenant commander in the British Royal Navy during the Gulf Warsaid new entrepreneurial healthcare and biotech investment opportunities were opening for family investors from the disruptive revolutions in technology, stem cell therapy and mental health.

In an interview held before the coronavirus outbreak, the Chair of the Court of the London School of Hygiene and Tropical Medicine at the University of London, and chair or board member of Cellmedica, Vium and Cocoon Biotech, among others, tells CampdenFB which areas of investment she is personally interested in, the innovative trends she is seeing and what family investors need to know before entering the sector.

What is your outlook for investments in 2020?

Im hugely optimistic moving into the next decade. Whilst I think that one can always recognise that the geopolitical environment that we now operate in has markedly evolved in the last few years, whether that be the notion of risk, uncertainty, unpredictability, theres no doubt that has significantly evolved. Some of the driving factors behind that include global leadership, the climate evolution were living through, but ultimately the world of investment and the opportunities continue to be exciting.

When one looks across the field of health and innovation, were living in the so-called Fourth Industrial Revolution, and there is probably no sector that exemplarises that more than the health tech and life science sector. Today I would say the innovation coming out of our academic universities is as broad and as advanced as I have seen in the last 30 years of my career. I think the ability to access capital is just remarkable on a global basis, there are trillions of dollars that are out there in different parts of the economy, looking for innovation and looking for leaders to invest in. And, of course, we have a technology revolution that is ongoing, particularly driven by our ability to generate, curate and process data and deliver insights which are going to transform how we access and deliver healthcare and think about keeping people on a global basis well and healthy for longer and deliver improved therapeutics to reduce suffering.

I dont think I could be really more optimistic entering this new decade when it comes to thinking about the combination of equity with innovation and disruption and the evolution of the world I operate in.

What are the headwinds for investments in healthcare and life science?

The biggest concerns are around the well-publicised debates on pricing of technologies, particularly in the US, and how to ensure every individual can get equal access to health. Those two areas will continue to be debated and drive short-term cyclical uncertainty. There is no doubt global leadership, and that includes the US, recognise that for stable societies, access to universal healthcare and the ability of populations to be happy, healthy and flourishing lies as the centre of their political ambition.

Which healthcare investments are you excited about?

The cross-cutting themes that I am particularly excited about when it comes to technology are the ability for machine-learning and AI [artificial intelligence] to generate algorithms and therefore products that can be placed into the hands of individuals for them to manage, track and improve their health.

For example, there are products coming along in the area of mental health and wellness where individuals increasingly in the future will be able to access through their mobiles programmes and support services which will help them track their mood and maintain their wellness. We know that many diseases, for example, of the gastrointestinal system like irritable bowel syndrome, are markedly impacted by mental health and wellbeing. Interventions such as digital therapeutics, such as apps that are regulated and provided as therapeutics, are set to transform the way these diseases are managed. I am consistently looking for technologies that can be placed into the hands of individuals for self-directed and personalised prevention and care management.

Secondly, the ability of technology to improve the way we plan and conduct research and development on a global basis truly again going to be disrupted in the future by our ability to get large datasets in an ethical way to translate that into pre-clinical discoveries of new therapeutics. And then in the clinical setting to conduct novel clinical trials and to really change the way we bring new therapies to market, like new therapeutics, medical devices, diagnostics, biochemical markers across the board, so I am very interested in companies that are pursuing that.

Thirdly, the area of how do we optimise healthcare utilisation, the efficiency and the effectiveness, whether that be here in the UK in the NHS [National Health Service] or globally. Its absolutely clear that if we want to ensure affordable access to the top quality healthcare and outcomes for populations, were going to need embrace digital innovations, so companies that operate in that space are very attractive.

Those are the cross-cutting themes. If I look at the verticals, I would say to you, of course, there are very good investments to be made in the area of cancer and oncology. However, there is a marked amount of money in that space, its a little bit overpopulated. So for family offices and alternate sources of capital I would not be placing my money there at this point. I would be looking at counter cyclical trends, so areas that are perhaps now emerging. Areas such as womens health, otherwise known as Femtech, clearly now emerging as an area for investment and has been systematically underinvested in over the last 10-15 years. Cardiovascular disease continues to be the biggest killer and cause of illness on a global basis and yet it really hasnt received a lot of attention in investment. Were now seeing a wave of innovations and were starting to see more about the biology of heart disease, stroke and diabetes so again I would see that as an area of interest [as is] stem cells in therapeutics across a whole spectrum of diseases. Im particularly interested in Type 1 diabetes and the ability to generate beta cells for the production of insulin in patients with Type 1 diabetes. We are starting to see companies emerging and exploring that space so really stem cells and the cell therapy space, along with gene therapy is very interesting.

For family offices, the whole area of mental health and wellness is enormous and growing. The reason is its now becoming apparent people are talking about mental health and wellness in a way thats reducing stigma and then allowing money to flow into this space. How we deal with the human brain and preserving the health and wellness of the brain, both from an emotional and physical point of view, whether that be the prevention of degenerative brain disorders like dementia or the management of anxiety and all the related diseases known as depression, is a very interesting space for investment and its where I am investing in a lot.

How can family offices enter and succeed in the healthcare and biotech investment market?

Its extremely difficult as a family office to make an initial move into the sector, largely because its extremely complicated and it really rather depends on what the investment goals are and the returns that are desired. The sector is highly fragmented and family offices have traditionally and largely invested in the more sustainable, long-term world of pharma as part of a general equity portfolio. Were talking about a very different sector which is largely based on entrepreneurship, a lot of risk and deep science, so I think the first thing to say is that family offices, before moving into or when in this space, should ensure they have the access to the right expertise around the table. They can gain that either through their own networks of advisers or by participating through investments in a fund.

Often the best way to get started is to find a fund that meets the investment criteria of a family office and to start to invest through that. Not through a traditional VC fund, there are number of funds coming together with the sole purpose of accessing family offices, sovereign wealth funds, alternate sources of capital and then investing through that because its really important in the risky healthcare and life science sector to have a portfolio view that is very strategically put together. You have to be prepared to fail and to be prepared to be a long-term patient investor thats willing to along five-to-seven years for the ride.

Go here to see the original:
Dr Annalisa Jenkins on healthcare and biotech investments for family offices - Campden FB

Impact of COVID-19 on Stem Cell Assay Market In-Depth Analysis And Forecast 2020-2027 | By Top Key Players Merck & Co., Thermo Fisher Scientific,…

By Stem Cell Medicine

The Stem Cell Assay Market Has Witnessed Continuous Growth In The Past Few Years And Is Projected To Grow Even Further During The Forecast Period (2020-2027). The Assessment Provides A 360 View And Insights, Outlining The Key Outcomes Of The Industry. These Insights Help The Business Decision-makers To Formulate Better Business Plans And Make Informed Decisions For Improved Profitability. In Addition, The Study Helps Venture Or Private Players In Understanding The Companies More Precisely To Make Better-informed Decisions. Some Of The Prominent Key Players Covered In The Stem Cell Assay Market Are Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

Whats Keeping Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International. Ahead In The Market? Benchmark Yourself With Strategic Steps And Conclusions Recently Published By Coherent Market Insights

Read Detailed Index of full Research Study @ https://www.coherentmarketinsights.com/ongoing-insight/stem-cell-assay-market-1632

Type Segmentation:

By Product Type-InstrumentsReagents & KitsBy Cell Type Adult Stem CellsInduced Pluripotent Stem CellsMesenchymal Stem CellsNeural Stem CellsHematopoietic Stem CellsUmbilical Cord Stem CellsHuman Embryonic Stem CellsBy Process Cell CultureEngineeringDifferentiationCharacterizationOthersBy Application -ResearchDrug Discovery & DevelopmentRegenerative Medicine

Consumer Traits (If Applicable)

The Stem Cell Assay Market Study Covers Current Status, % Share, Future Patterns, Development Rate, Swot Examination, Sales Channels, To Anticipate Growth Scenarios For Years 2020-2027. It Aims To Recommend Analysis Of The Market With Regards To Growth Trends, Prospects, And Players Contribution To Market Development. The Report Size Market By 5 Major Regions, Known As, North America, Europe, Asia Pacific (Includes Asia & Oceania Separately), Middle East And Africa (Mea), And Latin America.

The Stem Cell Assay Market Factors Described In This Report Are:-key Strategic Developments In Stem Cell Assay Market: The Research Includes The Key Strategic Activities Such As R&d Plans, M&a Completed, Agreements, New Launches, Collaborations, Partnerships & (Jv) Joint Ventures, And Regional Growth Of The Key Competitors Operating In The Market At A Global And Regional Scale.

Key Market Features In Stem Cell Assay Market: The Report Highlights Stem Cell Assay Market Features, Including Revenue, Weighted Average Regional Price, Capacity Utilization Rate, Production Rate, Gross Margins, Consumption, Import & Export, Supply & Demand, Cost Bench-marking, Market Share, Cagr, And Gross Margin.

Analytical Market Highlights & Approach The Stem Cell Assay Market Report Provides The Rigorously Studied And Evaluated Data Of The Top Industry Players And Their Scope In The Market By Means Of Several Analytical Tools. The Analytical Tools Such As Porters Five Forces Analysis, Feasibility Study, Swot Analysis, And Roi Analysis Have Been Practiced Reviewing The Growth Of The Key Players Operating In The Market.

Get Request a Sample Copy @https://www.coherentmarketinsights.com/insight/request-sample/1632

Table Of Contents:

Stem Cell Assay Market Study Coverage: It Includes Major Manufacturers, Emerging Players Growth Story, Major Business Segments Of Stem Cell Assay Market, Years Considered, And Research Objectives. Additionally, Segmentation On The Basis Of The Type Of Product, Application, And Technology.

Stem Cell Assay Market Executive Summary: It Gives A Summary Of Overall Studies, Growth Rate, Available Market, Competitive Landscape, Market Drivers, Trends, And Issues, And Macroscopic Indicators.Stem Cell Assay Market Production By Region Stem Cell Assay Market Profile Of Manufacturers-players Are Studied On The Basis Of Swot, Their Products, Production, Value, Financials, And Other Vital Factors.

Key Points Covered In Stem Cell Assay Market Report: Stem Cell Assay Overview, Definition And Classification Market Drivers And Barriers

Stem Cell Assay Market Competition By Manufacturers

Stem Cell Assay Capacity, Production, Revenue (Value) By Region (2019-2027)

Stem Cell Assay Supply (Production), Consumption, Export, Import By Region (2019-2027)

Stem Cell Assay Production, Revenue (Value), Price Trend By Type {strip Sensors, Invasive Sensors, Ingestible Sensors, Implantable Sensors, Wearable Sensors}

Stem Cell Assay Market Analysis By Application {hospitals, Ambulatory Surgical Centers, Diagnostic Centers}

Stem Cell Assay Manufacturers Profiles/analysis Stem Cell Assay Manufacturing Cost Analysis, Industrial/supply Chain Analysis, Sourcing Strategy And Downstream Buyers, Marketing Strategy By Key Manufacturers/players, Connected Distributors/traders Standardization, Regulatory And Collaborative Initiatives, Industry Road Map And Value Chain Market Effect Factors Analysis.

Get Updated PDF Brochure of this Report @https://www.coherentmarketinsights.com/insight/request-pdf/1632

Thanks For Reading This Article; You Can Also Get Individual Chapter Wise Section Or Region Wise Report Versions Like North America, Europe Or Southeast Asia Or Just Eastern Asia.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email: [emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

See the rest here:
Impact of COVID-19 on Stem Cell Assay Market In-Depth Analysis And Forecast 2020-2027 | By Top Key Players Merck & Co., Thermo Fisher Scientific,...

Exploring the Utility of Stem Cell Therapy for COVID-19 – Technology Networks

By Stell Cell Research

Whilst the production of a safe and effective vaccine for SARS-CoV-2 is the ultimate aim of the COVID-19 response, research is also underway to develop novel treatments that could help infected patients in the meantime. One growing area of interest is the use of stem cell therapy: the results of two studies conducted in China indicate that its use seems to be particularly efficient in the case of severely ill patients, and theUS Food and Drug Administration recently authorized compassionate use of mesenchymal stem cell intravenous infusions in patients with a very dismal prognosis.To learn more about the science behind stem cell therapies andhow such a therapy would be produced and administered to COVID-19 patients,Technology Networksrecently spoke with Giuseppe Mucci, CEO, Bioscience Institute.

Anna Macdonald (AM): Can you explain some of the immunomodulatory effects stem cells can have and why this is particularly significant for COVID-19 patients?Giuseppe Mucci (GM):Mesenchymal Stem Cells (MSCs) are multipotent cells found in various locations in the body including adipose tissue, bone marrow, placenta and umbilical cord. These cells can be easily harvested, isolated, cultured and used in cell-based therapy, from basic research to clinical trials. Safety and effectiveness have been clearly documented in many clinical trials, especially in the immune-mediated inflammatory diseases, such as graft versus-host disease and systemic lupus erythematosus. MSCs play a positive role mainly in two ways, namely immunomodulatory effects and differentiation abilities. MSCs can secrete many types of cytokines by paracrine secretion or make direct interactions with immune cells, leading to immunomodulation.

The immunomodulation activity of mesenchymal stem cells was further confirmed in an interesting two-year-longclinical trialcarried out by the University of Miami, where the researchers used these cells for the treatment of frailty. We also know that the immunomodulatory effects of MSCs are triggered further by the activation of toll-like receptors in MSCs, which is stimulated by pathogen-associated molecules such as lipopolysaccharides or RNA from a virus, such as SARS-CoV-2.

Several reports demonstrated that the first step of COVID-19 pathogenesis is that the virus specifically recognizes, infects and destroys cells via two specific molecules, ACE2 and TMPRSS2. Unfortunately, the ACE2 receptor is widely distributed on the surface of human cells, especially lung alveolar cells, capillary endothelium and on some cardiac cells.

The immune system and its regenerative ability is compromised by age and, unfortunately, as we know very well, the elderly are strongly hit by this disease. Studies of the outbreak so far show that eight in 10 patients who are struck down with a severe case of coronavirus will be over 65. People under the age of 50 are supposed to have healthier immune systems than those who are older. This means their bodies should recognize an alien agent, such as the novel coronavirus, fairly quickly after it enters their cells and start producing antibodies to fight it.

Before the virus has had time to cause any of the serious breathing problems and nasty pneumonias in the lungs, their immune system should have fought it off, and they should be well on the road to recovery, suffering only a fever, dry cough and fatigue.

However, it is the youthful immune system that may become the problem in some subjects. As the immune system recognizes and prepares to attack the virus, small unknown and otherwise harmless genetic or environmental factors can cause the immune system to go into overdrive.

Inflammatory cells can release an excessive quantity of cytokines, which should help produce a hostile environment for the infection and sets off a chain event called a "cytokine storm". This is an over-reaction on the part of the immune system. This means thatthe immune system is unable to turn itself off once it has generated enough of a defence against the virus. Inflammation caused by the immune system continues at an unchecked and accelerated rate and floods the lungs with fluid, making it difficult to breathe. A prolonged cytokine storm will eventually shut down breathing completely.

Mesenchymal stem cells used in patients that have been affected by the cytokine storm may fine balance the immune system in order to stop the overreaction, without switching it off completely, so that the immune system can continue to fight the infection.

In elderly patients, MSCs may support the immune response as already proved by the Florida University trial and support the healing process absolutely necessary after the damage generated by the virus.

Molly Campbell (MC): The FDA has approved compassionate use of MSCs, specifically allogeneic (from a donor) stem cells. For our readers that may be unfamiliar with the approval processes, what does this mean?GM:Compassionatedruguserefers to the useof a new, unapproved drug to treat a seriously ill patient when no other treatments are available. To date, there is no specific cure for COVID-19. Clinical management of these patients currently includes prevention or control of the infection and supportive care, including supplemental oxygen and mechanical ventilation support when needed.

MSCs are recognized by the FDA as well as the European Medicines Agency (EMA) as a therapy that has already proven to be safe and in several cases effective in a number of American and European trials. Considering this and the early Chinese study reports regarding the efficacy of MSCs in the treatment of severe COVID-19 patients, FDA has granted compassionate use approval.

We can use MSCs obtained from your own tissue (autologous use) or from another individual's tissue (allogenic use). For several reasons, autologous use is the elective way, but considering that the production of the cells can take a considerable amount of time and we are currently in an emergency situation, if the patient has not already banked MSCs the only option is allogenic use. These cells can, in some way, evade the normal rules of self and not self that usually regulate the organ and tissue donation, and this allows allogenic use.

MC: Please can you tell us more about the results of the studies that have been conducted in China?GM:Two recent studies have taken place in China, and both studies reveal remarkable reversal of symptoms even in severe-critical conditions. The scientists have not only identified a novel therapeutic strategy, but also the existence of natural mechanisms able to counteract acute inflammatory pneumonia.

One study is a case reportof a critically ill COVID-19 patient on a ventilator who had progressed despite intensive therapy, with markers showing evidence of liver injury. This patient was treated with allogeneic MSCs using three intravenous infusions of 5x107MSCs, three days apart. Within four days of the patient's first cell infusion, she was off the ventilator and able to walk. All measured parameters, including circulating T cell counts, returned towards normal levels. No obvious side effects were observed.

The second study, the Beijing YouAn Hospital study, was a pilot clinical trial to assess whether MSC transplantation could improve the outcome of seven enrolled patients with clinical COVID-19 pneumonia, with one case determined as critically severe, four severe, and two non-severe. Before transplantation, all individuals had high fever, shortness of breath and low oxygen saturation. Treatment included a single intravenous dose of clinical grade MSCs, 1x106cells per kg of weight. Detailed follow-up over 14 days post-transplantation showed no adverse effects, and within two days all patients had significantly improved pulmonary function, including the one severe COVID-19 pneumonia case, who was well enough for discharge by day 10. Overall, after treatment, the immune system in a cytokine storm-like condition returned to a normal status.

MC: Please can you talk us through how a stem cell therapy would be produced and administered to COVID-19 patients?GM:MSCs can be isolated from several sources including adipose tissue, bone marrow, placenta, cord blood tissue etc. The harvested tissue is transferred to a Good Manufacturing Practice compliant cell factory where the cells of interest are isolated. The number of cells that can be isolated from the tissues is very low and not sufficient for therapeutic protocols, which require hundreds of millions of cells. That is why we need to expand them in a culturing process that normally requires two to four weeks. Once the cells are ready, the patient will receive the cell-based drugas intravenous infusions.

MC: Does data exist on which time-point post-infection the therapy would produce the highest efficacy?GM:At the moment, MSCs based therapy is used as emergency protocol mainly for the control of the cytokine storm when the patient is in a severe condition. However, as several studies have already shown, these cells can be used as a preventative treatment especially in the elderly patient.

MC: Are there safety implications to developing a stem cell therapy for treating COVID-19?GM:To claim that the development of a novel therapy, regardless of what it is, is free of risk is not scientifically and ethically correct. The data available at the moment has not reported side effects linked with the use of MSCs when the cells are produced by reliable groups with strong and validated quality systems.

Giuseppe Mucci, was speaking to Molly Campbell and Anna MacDonald, Science Writers, Technology Networks.

See the original post:
Exploring the Utility of Stem Cell Therapy for COVID-19 - Technology Networks

→←